Let's get started. We have Axon CFO and COO Brittany Bagley with us. Super excited. Thank you for joining.
Thank you for having me here.
A lot to get to, but maybe we'll start off with Skydio, the recent investment that you made. Rick had noted that this is the biggest decision Axon has made in its recent history, a large acquisition of $1.2 billion, which is a 37%, or increases your ownership stake in Skydio to 37%. With that agreement, you also negotiated an exclusive disti agreement for U.S. and Canada public safety. Maybe if you could help us think through the economics and the structure of the deal, why this structure versus an all-out acquisition?
Yeah. No, thank you for the question. We've been partnered with Skydio for a couple years now, and they really are our Drone as First Responder partner. We've continued to deepen that relationship. We have a tremendous amount of respect for the team and the technology, and we really think they're going to be the leader in American-made drones, and we've only increased that conviction as we've worked with them. As we were talking to them, we wanted to just continue to further deepen that relationship, and so that included getting the exclusive distribution agreement for the U.S. and Canada. We will now be their channel for public safety in the U.S. and Canada. It allows us to really have a very aligned go-to-market strategy for those customers.
It allows us to really be aligned on what their roadmap is and get behind them, work together, work really closely. In addition to that, because they are going to be our sole partner and we're going to spend a lot of time and energy and investment behind them, getting them into our customers and our channel, we wanted to increase our ownership of the business. That's a belief in the management and the team, and also a belief in how much value we're going to help drive together with them. So that's why we made the additional investment. We took our stake up to about 37%. That more than doubled it. We added about 20 points of ownership for that. I will say we released an 8-K this morning. We've slightly tweaked the structure of how we were doing that.
It was originally a mix of cash and equity, and we've moved that to be predominantly cash. We're now going to make that a 90% cash deal. Just if anybody's been watching our share price, we didn't want to issue equity at the share price level, so we've moved that to be cash. There is still a small equity component, and that's going directly to Skydio as primary, and that's really to have them and us closer aligned. So we have an ownership stake in them, and they have an ownership stake in us just to really solidify that relationship. We couldn't be more excited for them and what they can do for our customers and what they can do for our ecosystem. We talk a lot about having everything from sort of call to closure, going all the way through.
Now from 911 at the very beginning all the way through to being able to deploy a drone that works really seamlessly in our ecosystem.
Great. That's very helpful. Appreciate the 8-K flag to the 90%. Maybe just digging in a little bit on the connected ecosystem. Maybe help us better understand how it connects to Axon 911, Fusus, body cameras, broader AI solutions. How does that improve DFR and just general competitive landscape in this growing drone market space?
Yeah. Over the last couple of years, we've significantly expanded our product portfolio, and that's both organically and inorganically, and you can see that in that whole ecosystem. Now it starts as soon as a call comes in through 911. We have both Prepared and Carbyne doing either an AI overlay or Carbyne as the underlying call handling software, all the way through Fusus, which was one of our acquisitions, which is doing incredibly well. It's the backbone of this information, getting in all the sensors, all of the data, helping develop a true real-time crime center platform for these customers. Obviously, we have a lot of sensors out there between the TASERs and the body cameras and the Axon Fleet cameras. There's ALPR, just all the sensors out there in the field gathering this data, pulling them in, having Fusus ingest them.
As a customer needs to dispatch a call, now you have the ability to dispatch drones through Skydio, but you also have a lot of intelligence overlaid on top of that, and that's a lot of what our AI work is doing. I think AI translation on the body camera is a big part of that. Those software pieces of how do we make the video that the body camera ingests, or how do we make the actual interaction between the officer and people in the real world, how do we make that more intelligent? How do we make that more seamless? That's where a lot of our AI is going. Obviously, the AI piece we've been doing organically.
I think as you think about where do we go, we've announced some new products like Axon Gravity, which really just starts to further pull all of this together, or Axon Assistant, which continues to make it easier in the field for officers.
Thanks, Brittany. Before we move on to a bunch of other topics, just quickly maybe, what's the appetite for additional M&A going forward? Is the pipeline strong, or are you content with integrating 911, Prepared, Carbyne, Skydio, and building out those new AI products that you just mentioned, Gravity, et cetera?
Just Skydio, so I think that uses our capacity for a while. I would say the way we do M&A is we often invest in companies first. We get to know them, we build the relationship, and then we make a decision on whether or not they are better coming into our portfolio and being a first-party product from us, or if they are better as a partnership. Obviously, we have decided that Skydio is a great partnership. It allows them to continue developing their roadmap. They have got a team, they are a scrappy startup, they are moving really fast, and they have a lot of markets that we are not playing as closely in.
I would contrast that to something like Fusus, where we invested in them, we partnered with them, and then we decided that that would really be better in-house, fully integrated across all of our products. There is obviously nothing I am expecting in the near term, but I would say as we look at M&A in the future, we will probably make some investments. I think we have a really good sort of holistic product portfolio now, sort of that from call to the end, so there are no big categories we feel like we are missing right now.
But I think we are always watching new companies that come in. We tend to like to buy smaller companies where we are really buying technology or talent. That is very different than buying sort of big, fully-fledged "accretive deals." But it has worked really well for us when you think about how Fusus has developed or how Dedrone has developed.
Okay. Thank you. Since you mentioned Dedrone, in 3Q, you noted three large deals totaling about $130 million. Some of that was delayed, not canceled. A lot of that was due to factors outside of your control, election, procurement. There is just maybe larger deals. It is something relatively new to Axon, although clear visibility into growth. So I guess just how should we think about the visibility into that $130 million converting to revenue maybe in 2027 or 2028 or over time, and then just that general new framework of working with these big, large deals on the federal international side?
Yeah. That is a great question. So, one, I would say Dedrone continues to perform really well. It is in our Platform Solutions segment, which still grew over 100% in the quarter. So, I would not say that these big federal deals are the only thing that is driving Dedrone. We are both still getting federal deals, and we have a really nice state and local business for Dedrone. But there were some big federal deals that we thought would come in in Q3 and Q4, and we expect that to be a timing piece. We expect those to push out, I am going to say hopefully 2027, but there is a little bit of that timing piece that is out of our control. This is relatively new technology. There are trials. Our customers are figuring it out.
Without a big event, like one of the great things about World Cup was it was a big event that sort of pushed the timing of these decisions. Without something that pushes the timing, what we are finding is that these can drag on. I do not think it is fundamentally changed anything in our view of Dedrone or the opportunity, but it is the timing. We called it out for this year. Without the deals, we still expect to grow approximately 30%, so we are still really happy with how the business is performing, and we are still happy with the long-term trajectory.
But I think what you will see is, at least until we get the Dedrone federal business big enough that a deal slipping out here or there does not really matter, you will see us sort of call these out and try and give you some context of to what we are assuming and when we think they are coming.
Okay, that is great. Then maybe sticking with Q3 results, AI was a standout. AI products surpassed $100 million in ARR. The broader software run rate approaching about $500 million , even plus doubling year-over-year. Thinking about AI becoming a billion-dollar-plus run rate business, what is the path there? What are the individual products that are going to get you there, whether it be Draft One, Translation, Guardian? Just better us understand those products and the incremental attach.
Yeah. Thank you for that question. I do feel like Dedrone sort of overshadowed our software business in Q3, and our software business is performing incredibly well. In addition to the $100 million of ARR, we talked about having $500 million of ARR from some of those newer software product categories. That includes things like Fusus and the software from Dedrone and 911, and AI, of course. Those software businesses that we have been investing in are really growing, and they are performing, and they are paying off. I think that is what you will continue to see. We did not have AI products two years ago, so these are really new categories for us. I think we expect really nice continued growth from them. We are so early in the penetration. The only thing I would note is, our customers do tend to sign longer-term contracts.
Some customers will come in, and they are adding an AI. Some customers are using that as a reason to rewrite their contracts. There are also customers who will come up for a contract renewal over the next five-plus years, where we have an opportunity to get them to come into AI. In terms of products, it is all the ones you mentioned. Draft One is really popular. Our new Translation product is really popular. We are getting great feedback on that. Axon Assistant is relatively newer. We are excited for that one. Our pace of innovation is just fast. We are constantly coming out with new products and new offerings. That is why our customers like the AI Era Plan, because they get everything new that we come out with.
Yes, the growth will be driven off of what we have today, but the growth is also going to be driven off of the things that we develop this year, next year, the year after.
That is great. We briefly touched on it a little bit, but how should investors think about the attachment and penetration of more, not the AI, just the software products, I guess, within your broader customer portfolio or product portfolio and demand pipeline for software in particular?
Yeah. I think there is still a good amount of room to go. We still have a number of customers who have room to upgrade and migrate onto some of our more premium programs and premium plans. I would say that is true for, if you think about our digital evidence management software, that is still growing nicely. Then we have all of these newer products on top, which are a much smaller portion of the penetration. I think you will see the newer products really driving some nice upside growth, but the whole software category is performing well.
Yeah, that's great. The results and the bookings strength, particularly in 3Q, definitely underscore that strength. Okay, so maybe if we moved over to TASERs, body cameras, it's really been the core foundation of the ecosystem, at least from our point of view. Investors do seem a little bit worried about potentially a slowdown. That said, TASER 10, you signed the largest deal ever this past quarter. I was at IACP where you introduced AB5, TASER Ion, got to test them out, very cool products. I guess, how do you think about the next phase of growth for these established categories, maybe some new innovations within the categories, and also expanding beyond traditional replacement cycles with that?
Yeah. It's a great question, and we've gotten a lot of those in the quarter. I would say first for Q3, TASER 10 grew, and we called out that AB4 grew about 25%. That means our overall Connected Devices business didn't, but a lot of that is because some of the older products are growing more slowly, which, given how long AB4 has been out for and the announcement of AB5, I think holds together logically. You would imagine that we're going to make an AB4 to AB5 transition. We've talked about it coming in the Q2, Q3 of next year, and it's already out there and customers see it. We are going through that migration cycle.
I would say TASER, again, to your point, we had our largest ever TASER 10 deal in Q2, so there is some lumpiness in TASER, but we continue to have a pretty large portion of our outstanding customer base that still has the opportunity to migrate from TASER 7 to TASER 10. We've been out with TASER for almost four years at this point, and so you can imagine on a five-year life cycle that at some point we'll be thinking about what our next TASER product is. I do think in our core customers, like state and local, this is a bit of an upgrade business on TASER and AB5, and so you can imagine as we're coming into something like AB5, we're going to be going through that upgrade cycle. I wouldn't discount that we continue to have great opportunities for new customers, though.
We talked about having really fantastic deals with corrections in Q3. Corrections is a big new market for us for both TASERs and body cameras. We have federal customers for TASERs and body cameras. We have international customers for TASERs and body cameras. There's a lot of opportunity outside of core state and local. I would say it's really two-pronged. One is you have the natural upgrade cycles in our core base. Again, we're still selling AB3s, we're still selling T7s, so there's a long time that it takes to migrate, and these products last a long time, and then there's our new growth categories. I would say even without the big federal deals, overall, we're expecting 30% growth for the year, so that's still a very, very healthy underlying business.
Yeah, absolutely. Just in terms of the Ion, it is maybe a different use case or a different end user than the traditional TASER.
Yeah.
It is new, so maybe it is worth touching on briefly.
Yeah. No, great point. Thank you. Yeah, we announced Ion at IACP, and we got really good feedback. So Ion is a smaller TASER, and it is really designed for people who cannot overtly carry TASERs on their duty belt. So it opens up a new market for us of undercover officers or anyone who is not basically in uniform but would like to have an alternative. So, that is a nice new category and a new market for us, even inside of TASER, and it got really good early feedback.
That is great. That is fantastic. So, we do get a lot of questions around gross margins in general. 3Q maybe came in slightly, like a little 59%, a little higher, but slightly below historical levels. There was some product mix in there. Obviously, everyone is struggling with memory and component cost increases. So just thinking about the puts and takes for 4Q and 2027 in the gross margins. You still were able to raise EBITDA by 10 basis points for 2026, so that is great. But I guess just help us better understand, obviously margin is a huge topic for everyone, especially at the TMT Conference this year, so.
Yeah, which makes sense because of what's going on with component costs. I would say if you look at it from a mix shift standpoint, you can roughly balance those out. We have some mix headwinds from some of our newer products that we're still scaling, but then we have some mixed tailwinds and benefits from software and the growth we're seeing in software. Then we have memory on top of that and the component cost increases that we're seeing in the supply chain, really driven by the demand from the hyperscalers and data centers, which you're probably all very well aware of. That was about 50 basis points of impact that we're expecting for this year from a memory standpoint. Most of that is hitting us in Q4, and that's just because of how we do inventory and the timing.
Through the beginning of the year, we had an ability to basically sell products with memory that had been at lower prices. I think you can imagine Q4 will be a pretty good proxy from a gross margin standpoint in terms of going forward. We called out that if it's 50 basis points mostly in Q4 and we've got four quarters of that next year, you can do the math on it. Then you have to factor in the software growth, and so I wouldn't just take 200 basis points out of gross margins. I would just imagine that that is a headwind that is offsetting benefits that we would otherwise be getting from software. Then you look at adjusted EBITDA margins, and to your point, we have that headwind this year. We're still expecting higher adjusted EBITDA margins. We took guidance up.
It is on us to offset those headwinds in OpEx and figure out how we can get more leverage. We're not calling out that there's anything catastrophic happening. I would imagine EBITDA margins next year are approximately flat from this year. We don't have guidance out there, but I think that would be a good ballpark of here's what, rather than having our OpEx leverage expand our margins like it has been, it's going to offset those memory impacts, but it is still happening. We still are leveraging our OpEx.
Okay. Yeah, that's great. OpEx was going to be my next question, but I guess just briefly, in terms of mix, professional services has been popping up a little bit on a few of the earnings calls. With the new AI products rolling out, is that, and I could be off here, but is that a function of just police officers or law enforcement, they don't have very strong, I don't want to call it a background in AI or technology. Is that what's driving that, or is there something else? Is there a different way to think about it?
A mix. Some of our newer products require professional services to get installed. I think Records is a good example. We've seen some nice adoption of our Records product that's showing up in the software growth, but that has services. We've always talked about Fleet having services. ALPR has professional services. I would say some of our current AI products, like Translation, there's not a lot of professional services associated with that. But as we think about something like Axon Gravity, that's really going to pull a lot of information together, something like that will have set up and have professional services. So you're just seeing a little bit of a mix as we get some of these newer products off the ground, or as we're ramping, they have some professional services associated with them. We still talk about our core software margins being above 80%.
The difference between that above 80% and what you're seeing, 75-ish percent in our software and services line is just that delta. I think that's probably a roughly good assumption going forward, that software stays above 80%, but that category stays in that mid-70s. Maybe it bounces around a little bit depending on mix each quarter. But we're also, you see what the professional services is unlocking and the growth of some of the segments.
Yeah, certainly a longer-term tailwind. But I guess moving on to free cash flow. So you've been transparent about the strategic inventory builds this year, some of the headwinds around free cash. So you're targeting around 40% conversion in 2026, stepping up in 2027, and then ultimately reaching 60%, which your target goal by 2028. So I guess thinking about the inventory build still continuing in early 2027, should we expect conversion to land somewhere in the middle of 40%-60% range in 2027, or is the recovery more back half weighted? Just help us think about cash generation. Thank you.
Yeah. I think that's a good assumption. I would say we expect to be through some of the inventory build, I'm going to conservatively say by Q2, because even if we have all the target inventory in Q1, we're still paying for it in Q2. So I would say you'll see sort of by the first half, we're hoping that we've gotten to a normalized inventory level, and then you'll see us start to work on the free cash flow generation from there. So I think it's a really good assumption to assume that 2027 is sort of in the middle of where we landed this year and where we'll land in 2028. And then I would say even this year, yes, we have the inventory investments.
You can also imagine one of the reasons free cash flow is a little bit lower than we were expecting this year is if you take those Dedrone federal deals and you think about it, like having had $130 million of revenue that we thought would hit this year, that goes all the way down to free cash flow in terms of inventory and timing of payments and stuff. We had to adjust our free cash flow along with our revenue for this year. But again, we will get that in at some point, and it will be a nice addition to both.
Yeah, that makes a lot of sense, and it does seem like this year is setting up for stronger fundamental growth in the years to come, and with all the new product launches, it should be great. I guess moving on to maybe longer-term opportunities. ALPR, license plate reader, is something that it has been in the news a lot. From my point of view, and please correct me if I am wrong, is that ultimately the way Axon approaches building trust and having a good reputation within the communities and law enforcements that it serves is that maybe your biggest competitors' headwinds ends up being a tailwind for you, just given the work that you have done to build and establish that trust in the community.
Any thoughts on ALPR? Because it is something that investors bring up all the time, and it is very visible in the news and within Congress, et cetera.
Yeah. Yes, it has been very visible. I would say the good thing is, again, approximately 30% this year with an ALPR business that is relatively small, and there has certainly been lots of headlines. I think it is a balance because it has been an incredibly helpful technology to our law enforcement customers. They are really passionate that it has been one of the biggest things that has helped them change and bend the curve on their ability to prevent and solve crimes that they see. Yet, that is a real balance with what the community wants and how this data should be used and what is acceptable.
For us, at the end of the day, for ALPR, like for all of our products, we really want to enable police and the community to work well together and have this balance between collecting information and solving crimes and what people are comfortable with.
We built our ALPR product with that in mind from the very beginning. We are putting that into our customers' hands, and they are working with their communities on what are retentions and retention policies, and when can that be accessed, and we are more than happy to enable anything that works for them there. Yes, some contracts have moved over to us because of that, and I think there will just be a period of time where there is a lot up in the air about ALPR. Some contracts have moved to us. Some communities have completely pulled out of ALPR. I think it will be a balance in the next couple of years as we figure out where that works, but it is still a really important tool for our customers. Over the long term, that will continue to be a growth area for us.
Okay, that is great. Another one of the emerging growth opportunities, enterprise, the Axon Body Mini body cam began shipping in the summer, I believe. I guess maybe what is some of the early data from the trials that you have out there with current customers? Then we will, I guess, have a follow-up after that.
Yeah. I would say early feedback on Axon Body Mini from our customers is really positive. There are two big markets that that is going into. One market is retail, and the other is healthcare. Both of those have sort of different nuances to why they want it and how they want to roll it out, but early feedback is positive. I still think you should imagine, because those are newer segments where nurses or retail associates haven't typically worn body cameras, you can imagine it will take a little bit of time for them to move from trial to full deployment to gaining broad acceptance for that in the market.
One of the most interesting things, or I think strongest parts about the Axon business, is the network effects. If I am a police chief of town A and body cameras, TASERs are working great, then I will call town B's police chief and say, "Oh, hey, by the way, you should take a look at some of these products that Axon has. They are phenomenal." Is there network effects in the retail space? Is Target going to call Walmart, and Walmart going to call Kohl's and say, "Oh, hey, this dropped shrinkage in my store by 10%." I mean?
Yeah. It is probably not quite as collaborative as the law enforcement community, but actually there are big asset protection conferences, and they talk to each other about this. We do have our enterprise customers referencing for each other. I do not know that I would put it at the same level of law enforcement, but there is, there is a network effect, and it does exist. It is more than just our Axon Body Mini, so we are excited for that. Fusus sells into our enterprise customers. Dedrone sells into our enterprise customers. Skydio will sell into our enterprise customers. We are starting to get a broader portfolio of products that really appeals. Not only is there a network effect between our customers, but there is actually a network effect with our products.
As we get in with one product to a customer and do a good job and delight them, that opens up the opportunity to sell more of our portfolio in.
Thank you. That is very, very helpful. About 40 seconds left. Maybe thinking about from your point of view, what is the single most underappreciated part of the Axon story, and where do you see the company going over the next three, five, 10 years?
Yeah. I think I would have said prior to this quarter that the sustainability of our software business was underappreciated. I know that there is a lot of questions out there about what software is going to be sustainable, but I really think, whether or not it is our AI products or our evidence management platform, that software is incredibly valuable and important to our customers. I think coming out of this quarter, there is a lot of concern about what does that look like for us long term. I think right now maybe what is underappreciated is that core business is going to continue to perform well. We still have long-term targets out there. You look at what we did without the big Dedrone federal deals this year, and it is still 30%.
There is no reason to assume we cannot keep going in that mid-20s at least kind of growth rate for the long term.
Perfect. Great place to wrap. Thank you, Brittany. Thanks, everyone, for attending.
Thank you.